Preclinical evaluation of l-asparaginase and methotrexate administered at intermediate doses in dogs

Hattie B. Bortnowski From the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI 53706.

Search for other papers by Hattie B. Bortnowski in
Current site
Google Scholar
PubMed
Close
 DVM
and
Robert C. Rosenthal From the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI 53706.

Search for other papers by Robert C. Rosenthal in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Click on author name to view affiliation information

SUMMARY

The role of l-asparaginase (l-asp) in limiting signs of methotrexate (mtx) toxicosis was studied. Eight dogs were randomly allotted to 2 groups of 4 dogs. All dogs were given 400 iu of l-asp/kg of body weight im, on day 1. On day 10, group-1 dogs were given 3 mg of mtx/kg, iv, and group-2 dogs were given 6 mg of mtx/kg, iv. All dogs were given 400 iu of l-asp/kg, im, 24 hours later (on day 11). One group-2 dog was euthanatized on day 16 because of severe gastrointestinal signs that were unresponsive to treatment. A second dose of mtx, identical to that given on day 10, was given on day 20 to each surviving dog, followed by l-asp on day 21. On day 67, the 7 surviving dogs were given 3 mg of mtx/kg, iv. Adverse reactions observed were vomiting, diarrhea, and weight loss. Gastrointestinal side effects of mtx were not attenuated with l-asp and would be a serious limitation to use of mtx administered at an intermediate dose in the treatment of lymphoma in dogs.

SUMMARY

The role of l-asparaginase (l-asp) in limiting signs of methotrexate (mtx) toxicosis was studied. Eight dogs were randomly allotted to 2 groups of 4 dogs. All dogs were given 400 iu of l-asp/kg of body weight im, on day 1. On day 10, group-1 dogs were given 3 mg of mtx/kg, iv, and group-2 dogs were given 6 mg of mtx/kg, iv. All dogs were given 400 iu of l-asp/kg, im, 24 hours later (on day 11). One group-2 dog was euthanatized on day 16 because of severe gastrointestinal signs that were unresponsive to treatment. A second dose of mtx, identical to that given on day 10, was given on day 20 to each surviving dog, followed by l-asp on day 21. On day 67, the 7 surviving dogs were given 3 mg of mtx/kg, iv. Adverse reactions observed were vomiting, diarrhea, and weight loss. Gastrointestinal side effects of mtx were not attenuated with l-asp and would be a serious limitation to use of mtx administered at an intermediate dose in the treatment of lymphoma in dogs.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 26 26 4
PDF Downloads 43 43 8
Advertisement